Neogenomics Inc.
NASDAQ:NEO
| Market Cap (Intraday) | 6.05B |
| Current PE | 84.37 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $49.06 |
| 50-Day MA | $46.14 |
| 200-Day MA | $47.95 |
Neogenomics Inc. Stock, NASDAQ:NEO
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida 33913
United States of America
Phone: +1.239.768.0600
Number of Employees: 1700
Description
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.